How the GLP-1 Drug Exendin-4 Changes Brain Chemistry in the Reward Center of Rats

This exploratory study used in vivo microdialysis in male rats — a technique that samples brain chemicals in real time through a tiny probe. Exendin-4 was administered either systemically (whole-body injection) or locally into the NTS. Researchers then measured changes in multiple neurotransmitters and their metabolites in the nucleus accumbens, including dopamine, serotonin, noradrenaline, glutamate, GABA, glycine, taurine, and serine.

GLP-1 drugs like semaglutide and exenatide are increasingly observed to reduce not just appetite but also interest in alcohol, gambling, and other addictive behaviors. This study helps explain the brain chemistry behind these effects by showing that a GLP-1 agonist changes neurotransmitter levels in the reward center. Understanding these mechanisms could open the door to using GLP-1 drugs for addiction treatment.

The observation that GLP-1 drugs reduce addictive behaviors has generated enormous interest. This study adds neurochemical detail to that picture by identifying specific neurotransmitter changes in the reward center. If confirmed, this could support repurposing GLP-1 agonists for alcohol use disorder, gambling addiction, and other compulsive behaviors — extending their impact far beyond metabolic disease.

This is a descriptive animal study that shows correlations but cannot prove causality. Only male rats were studied, so sex differences are unknown. The study used exendin-4, which may not perfectly replicate the effects of longer-acting GLP-1 drugs like semaglutide used clinically. The authors explicitly note the descriptive nature of the findings.